← Browse by Condition
Medical Condition

moderate to severe atopic dermatitis

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for moderate to severe atopic dermatitis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — moderate to severe atopic dermatitis Clinical Trials

How many clinical trials are currently recruiting for moderate to severe atopic dermatitis?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for moderate to severe atopic dermatitis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for moderate to severe atopic dermatitis?
moderate to severe atopic dermatitis research spans Phase 1 (2 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a moderate to severe atopic dermatitis clinical trial?
Eligibility criteria for moderate to severe atopic dermatitis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 3
2
Top Sponsors
TRex Bio, Inc. 1 trial
medac GmbH 1 trial
Sitryx Therapeutics Ltd 1 trial
Nektar Therapeutics 1 trial

Recruiting Clinical Trials

NCT06934252 Phase 1
Recruiting
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
Enrollment
115 pts
Location
Australia, New Zeala...
Sponsor
TRex Bio, Inc.
View Trial →
NCT06239311 Phase 3
Recruiting
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
Enrollment
277 pts
Location
Czechia, France, Ita...
Sponsor
medac GmbH
View Trial →
NCT07558668 Phase 1
Recruiting
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Enrollment
149 pts
Location
United States, Bulga...
Sponsor
Sitryx Therapeutics Ltd
View Trial →
NCT07690371 Phase 3
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Enrollment
510 pts
Location
United States
Sponsor
Nektar Therapeutics
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology